What we do
The University of Manchester's Imaging Facilities uses multi-modality imaging to advance the understanding of a wide range of human diseases and disorders, supported by an internationally renowned team of academics, clinicians and staff.
Research environment
The University's Imaging Facilities provide support for interdisciplinary research activities across the University, integrating the physical, biological and medical sciences. The Wolfson Molecular Imaging Centre houses the University's Positron Emission Tomography facility along with a radiotracer development programme, clinical and laboratory facilities, data analysis support and one of the University's 1.5T MRI scanners.
The University also owns a 3T MRI scanner housed at the NIHR/Wellcome Trust Manchester Clinical Research Facility and a 3T scanner housed at the Translation Imaging Unit, at Salford Royal Foundation Trust. Other facilities within the Imaging Facilities are housed at the Stopford Building on the University main campus.
What is PET?
Positron Emission Tomography (PET) is an imaging technique which produces a three-dimensional image to map the functional processes of the body using small amounts of radioactive material injected into the participant.
What is MRI?
Magnetic Resonance Imaging (MRI) is a non-invasive imaging technique which produces detailed images of the body's internal structure; MRI scans can also be used to map the changes in neural activity in the brain (functional MRI).
Stem Cell and Leukaemia Proteomics Laboratory (SCALPL)
The second floor of the Wolfson Molecular Imaging Centre is home to a completely different way of researching biomarkers and drug targets. It is home to the Stem Cell and Leukaemia Proteomics Laboratory (SCALPL). This group uses high end mass spectrometry and separation technologies to identify and quantify proteins or protein post-translational modifications central to disease processes. For example the identification of proteins that maintain leukemia stem cells leading to difficulty in eradicating them using drugs is pursued. The remit has extended in the last few years to biomarker discovery in plasma from patients undergoing treatment for cancer or who are at risk of malignant disease. Here the aim is to identify indicators of response to therapy or risk of acquiring disease using the high end mass spectrometry/proteomics platform.
Get in touch
How to find us, contact us, information on volunteering or search for staff
